worldwid
epidem
sar
sever
acut
respiratori
syndrom
due
newli
discov
coronaviru
sarscov
sarsassoci
coronaviru
reinforc
interest
coronavirida
famili
human
coronavirus
hcov
previous
alreadi
known
respons
mild
upper
respiratori
tract
diseas
sinc
two
member
famili
identifi
hcov
hcov
involv
seriou
respiratori
tract
infect
moreov
virus
show
environment
resist
increas
probabl
transfer
contamin
host
via
surfac
hand
etc
resist
lead
urgent
need
develop
effici
target
mode
prevent
treatment
vaccin
avail
cure
hcov
infect
fundament
dispos
adapt
antisepticsdisinfect
whose
effici
rigor
evalu
hcov
hcov
call
betacoronaviru
first
human
coronavirus
identifi
sinc
late
sixti
recogn
respons
upper
mild
respiratori
tract
infect
common
cold
follow
identif
new
member
coronavirus
infect
human
cours
sarscov
new
studi
conduct
clinic
featur
hcov
infect
inde
studi
routin
monitor
dealt
role
coronavirus
human
thu
epidemiolog
data
rare
like
result
precis
role
hcov
play
respiratori
tract
infect
greatli
underestim
import
note
virus
identifi
worldwid
human
coronaviru
infect
occur
mainli
winter
short
incub
time
recov
patient
sampl
respiratori
tract
infect
depend
studi
popul
hcov
strain
coronavirus
occupi
fourth
fifth
place
behind
influenzavirus
respiratori
syncyti
viru
adenovirus
rhinovirus
proport
gener
equival
one
metapneumoviru
parainfluenzavirus
sinc
implic
seriou
diseas
lower
respiratori
tract
bronchiti
bronchiol
pneumonia
croup
case
hcov
infect
concern
predominantli
weak
patient
newborn
infant
elderli
peopl
immunosuppress
patient
also
implic
nosocomi
infect
notabl
neonat
care
unit
hcov
suspect
caus
digest
dysfunct
first
associ
necrot
enterocol
newborn
diarrhea
gastrointestin
symptom
shown
accompani
coronaviru
infect
find
detect
viral
particl
coronaviru
rna
stool
sampl
presenc
hcov
antibodi
children
gastroenter
support
idea
howev
despit
argument
implic
human
intestin
infect
still
controversi
consid
evalu
potenti
rout
hcov
spread
anoth
debat
potenti
involv
hcov
central
nervou
system
diseas
multipl
sclerosi
support
bodi
evid
eg
neurolog
symptom
hcov
infect
patient
experiment
infect
neural
cell
hcov
detect
hcov
rna
antigen
brain
multipl
sclerosi
patient
recent
neuroinvas
properti
hcov
intranas
inocul
mice
howev
precis
real
implic
hcov
neural
diseas
yet
clearli
demonstr
furthermor
studi
report
also
heart
troubl
associ
hcov
infect
epidem
outbreak
due
sarscov
first
worldwid
epidem
centuri
began
guangdong
provinc
china
novemb
spread
world
within
month
new
coronaviru
quickli
identifi
thank
concert
intern
effort
novemb
juli
sarscov
affect
peopl
five
contin
caus
death
one
strike
featur
epidem
nosocomi
propag
heavi
burden
health
care
worker
moreov
mortal
rate
higher
age
popul
sarscov
infect
human
typic
caus
influenzalik
syndrom
malais
rigor
tired
high
fever
onethird
infect
patient
clinic
symptom
regress
patient
recov
persist
pulmonari
lesion
remain
twothird
infect
patient
diseas
progress
atyp
pneumonia
respiratori
insuffici
lead
respiratori
failur
common
caus
death
among
infect
sarscov
mani
patient
also
develop
wateri
diarrhea
activ
viru
shed
sever
week
might
increas
transmiss
viru
add
anoth
evid
gastrointestin
tropism
hcov
moreov
sarscov
receptor
angiotensinconvert
enzym
present
lung
also
gastrointestin
tract
sarscov
seem
predominantli
transmit
respiratori
droplet
rel
close
distanc
howev
direct
indirect
contact
respiratori
secret
fece
anim
vector
could
also
lead
transmiss
least
circumst
besid
pathogen
properti
coronavirus
repres
anoth
risk
human
popul
interspeci
jump
capac
suspect
hcov
may
evolv
bovin
coronaviru
respons
gastrointestin
infect
cattl
similarli
sarscov
zoonot
viru
cross
speci
barrier
phylogenet
analysi
sarscov
isol
anim
human
strongli
suggest
viru
origin
anim
like
bat
amplifi
palm
civet
transmit
human
popul
via
live
anim
market
potenc
coronavirus
may
respons
new
disastr
outbreak
therefor
kept
mind
treatment
vaccin
avail
fight
hcov
infect
case
sarscov
variou
approach
use
epidem
none
realli
success
target
treatment
essenti
empir
symptomat
depend
upon
sever
ill
sinc
studi
conduct
identifi
potent
antisarscov
treatment
standard
molecul
use
viral
infect
ribavirin
interferon
hydrocortison
use
lead
diverg
conclus
result
test
vivo
vitro
develop
strategi
monoclon
antibodi
sirna
molecul
glycyrrhizin
nelfinavir
conduct
vitro
still
need
improv
emerg
sarscov
also
led
develop
new
vaccin
strategi
includ
express
sarscov
spike
protein
virus
inactiv
sarscov
particl
dna
vaccin
howev
earli
concern
applic
sarscov
vaccin
experi
anim
coronaviru
vaccin
induc
enhanc
diseas
immunopatholog
anim
challeng
infecti
viru
inde
similar
immunopatholog
reaction
describ
mice
vaccin
sarscov
vaccin
subsequ
challeng
sarscov
thu
safeti
concern
relat
effect
safeti
vaccin
person
especi
expos
coronavirus
care
examin
decad
ago
studi
compar
surviv
rate
hcov
one
nonenvelop
viru
type
differ
condit
temperatur
humid
result
report
tabl
thu
aerosol
hcov
found
better
surviv
rel
humid
inde
nearli
origin
infecti
viru
still
detect
six
day
high
rel
humid
seem
less
favor
viru
unless
temperatur
came
temperatur
surviv
hcov
significantli
enhanc
whatev
rate
rel
humid
enhanc
surviv
rate
high
rel
humid
low
temperatur
may
explain
winter
propag
coronavirus
moreov
hcov
surviv
significantli
higher
rel
humid
polioviru
experiment
condit
could
strike
result
accord
nonenvelop
natur
sensit
sarscov
temperatur
also
assay
exposur
viru
temperatur
min
reduc
viru
titer
undetect
level
except
sarscov
associ
protein
fetal
calf
serum
fc
bring
protect
viru
case
temperatur
need
reach
min
bring
viru
titer
detect
limit
emphas
import
organ
materi
virus
could
embed
real
condit
could
protect
viru
mostli
disinfect
procedur
viru
place
loss
infect
anoth
studi
confirm
viral
stabil
also
least
hr
sarscov
lost
infect
min
exposur
respect
coronavirus
also
well
surviv
suspens
hcov
display
surviv
rate
respect
phosphat
buffer
salin
pb
three
day
respect
six
day
surviv
rate
came
hcov
hcov
three
day
cultur
medium
ten
day
viru
respect
studi
also
show
desicc
sever
effect
coronavirus
inde
standard
environment
condit
rel
humid
hcov
infect
came
three
hr
desicc
variou
surfac
found
hospit
set
aluminum
steril
spong
surgic
latex
glove
hcov
sensit
desicc
sinc
infect
detect
threshold
three
hr
dri
rabenau
et
al
made
compar
studi
stabil
differ
virus
ie
sarscov
hcov
type
simplex
viru
type
suspens
dri
medium
cultur
without
fc
hcov
progress
lost
infect
nine
day
consist
previou
studi
infecti
titer
three
virus
includ
sarscov
stabl
nine
day
without
protein
dri
plastic
surfac
hcov
lost
infect
hr
presenc
absenc
fc
contrast
sarscov
retain
infect
long
six
day
protect
effect
protein
took
nine
day
dri
state
sarscov
complet
lose
infect
adenoviru
stabl
viru
assay
conserv
infect
throughout
nine
day
experi
studi
confirm
result
sarscov
shown
surviv
dri
differ
kind
materi
dilut
water
reveal
decreas
infect
hr
depend
condit
howev
infect
reduc
rapidli
deposit
porou
surfac
cotton
paper
thu
rna
sarscov
found
differ
environ
sampl
chair
elev
comput
mous
etc
may
contribut
contamin
healthcar
worker
direct
contact
sarspati
recent
studi
implic
water
sewag
transmiss
sarscov
take
mhv
tgev
surrog
experi
time
requir
reduct
water
day
tgev
day
mhv
sewag
took
nine
day
tgev
seven
day
mhv
four
week
almost
condit
less
infect
decreas
virus
author
conclud
case
sarscov
reemerg
water
contamin
fecal
wast
consid
potenti
vehicl
transmiss
studi
firmli
illustr
potenc
coronavirus
especi
sarscov
transmit
via
rout
respiratori
droplet
like
risk
contamin
via
surfac
fomit
also
notic
residu
infect
envelop
virus
differ
condit
almost
reach
one
nonenvelop
virus
reapprais
environment
stabil
two
type
virus
sensit
coronavirus
ph
variat
establish
number
stabl
slightli
acid
ph
alkalin
ph
shown
hcov
mhv
tgev
canin
coronaviru
note
earlier
hcov
excret
respiratori
secret
also
biolog
fluid
fece
know
understand
viral
surviv
essenti
estim
risk
potenti
transmiss
rout
studi
conduct
sarscov
shown
surviv
least
hr
sputum
serum
fece
infect
level
nevertheless
lower
suspend
urin
noteworthi
sarscov
surviv
depend
kind
fece
whose
ph
may
vari
studi
shown
certain
surpris
result
regard
previous
quot
studi
inde
sarscov
surviv
beyond
hr
normal
fece
adult
beyond
three
hr
newborn
fece
slightli
acid
contrast
could
surviv
longer
four
day
diarrheic
fece
whose
ph
could
reach
ph
studi
reveal
sarscov
surviv
four
five
day
respiratori
specimen
accord
data
transfer
virus
crosscontamin
care
consid
inde
certain
circumst
instanc
healthcar
set
contamin
inanim
materi
peopl
infecti
respiratori
secret
bodi
fluid
saliva
urin
fece
seem
play
role
sarscov
transmiss
like
hcov
thu
essenti
dispos
adapt
target
effici
way
disinfect
whose
effici
correctli
evalu
absenc
treatment
high
mortal
rate
transmiss
pattern
sarscov
involv
set
power
coordin
mean
prevent
stop
worldwid
spread
viru
inde
sarscov
epidem
brought
control
thank
basic
public
health
measur
includ
rapid
case
detect
isol
contact
trace
quarantin
good
precautionari
control
measur
hand
wash
use
person
protect
equip
addit
express
recommend
travel
come
area
affect
sar
screen
potenti
case
inflight
care
suspect
case
follow
aircraft
disinfect
thu
besid
standard
measur
knowledg
hcov
sensit
antisepticsdisinfect
improv
order
use
fundament
prevent
tool
target
coher
manner
face
lack
antivir
treatment
necessari
develop
new
mean
prevent
ensur
exist
one
effici
accord
field
situat
proper
evalu
effici
antisepticsdisinfect
virus
thu
crucial
essenti
antisepticdisinfect
antivir
activ
evalu
combin
virus
product
test
appropri
precis
contact
time
accord
expect
use
product
surfac
hand
disinfect
instanc
product
activ
eventu
cytotox
neutral
loss
viral
infect
due
product
activ
estim
neutral
antisepticdisinfect
activ
play
key
role
test
procedur
ensur
precis
contact
time
elimin
residu
activ
cytotox
test
product
success
recoveri
virus
kill
product
test
requir
appropri
control
especi
check
absenc
interfer
viral
infect
due
test
also
import
test
neutral
remov
cytotox
reproduc
test
condit
eg
contact
time
environment
temperatur
germicid
consid
antisepticdisinfect
antivir
activ
induc
contact
time
reduct
viral
titer
higher
depend
american
european
regulatori
agenc
respect
neutral
step
play
key
role
methodolog
sever
differ
method
exist
achiev
neutral
first
one
neutral
dilut
theoret
allow
instantan
arrest
activ
test
product
elimin
cytotox
howev
requir
virus
high
titer
order
observ
reduct
viral
titer
afterward
case
frequent
observ
cytotox
elimin
thoroughli
make
imposs
titrat
viru
two
techniqu
avail
counter
drawback
chemic
neutral
associ
dilut
chemic
inactiv
test
product
cytotox
howev
neutral
avail
especi
take
account
huge
number
antisepticsdisinfect
gel
filtrat
method
allow
retent
antisepticdisinfect
molecul
antivir
activ
cytotox
releas
viral
particl
could
titter
yet
method
may
lengthen
contact
time
lead
overestim
product
activ
inde
precis
contact
time
fundament
respect
futur
use
condit
reflect
real
activ
product
field
differ
factor
consid
order
repres
futur
use
condit
product
close
possibl
differ
type
test
exist
differ
level
evid
suspens
test
use
screen
molecul
effici
cytotox
ii
carrier
test
allow
monitor
effici
product
virus
dri
differ
kind
surfac
iii
infield
test
instanc
hospit
set
rare
perform
cost
standard
problem
test
organ
materi
fc
fece
albumin
etc
could
even
ad
inde
virus
normal
found
embed
materi
protect
action
antisepticsdisinfect
moreov
signific
part
antisepticsdisinfect
chlorin
deriv
compound
inactiv
organ
materi
final
virus
known
aggreg
might
enhanc
presenc
organ
materi
make
even
resist
action
antisepticsdisinfect
one
challeng
antivir
antisepticsdisinfect
test
standard
obtain
valuabl
compar
result
illustr
next
section
even
result
concern
activ
antisepticsdisinfect
hcov
gener
consist
still
difficult
compar
extrem
import
set
standard
test
antisept
activ
date
one
european
standard
nf
en
virucid
antisepticdisinfect
activ
test
human
medicin
publish
protocol
januari
test
method
minimum
requir
establish
virucid
activ
accord
potenti
use
product
test
eg
disinfect
surfac
instrument
hygien
hand
wash
thermochem
disinfect
viru
strain
temperatur
contact
time
interf
substanc
potenti
use
accord
standard
product
consid
antisepticdisinfect
antivir
activ
induc
loss
infect
least
viral
titer
accur
contact
time
unit
state
princip
standard
rel
close
european
one
specifi
efficaci
criterion
sever
standard
publish
cover
differ
field
situat
two
standard
concern
evalu
hygien
hand
wash
standard
concern
evalu
efficaci
virucid
agent
intend
inanim
environment
surfac
final
specif
standard
concern
neutral
step
studi
sattar
et
al
evalu
effici
antisepticsdisinfect
variou
chemic
famili
four
differ
virus
two
nonenvelop
virus
type
bcoxsackieviru
type
two
envelop
virus
hcov
type
aim
view
viral
inocula
suspend
fece
mucin
mimic
organ
matter
left
dri
stainlesssteel
disk
contact
time
min
efficaci
criterion
reduct
viral
titer
result
gather
tabl
studi
highlight
fact
envelop
virus
sensit
nonenvelop
virus
action
antisepticsdisinfect
despit
sensit
discrep
within
group
howev
envelop
virus
fragil
inactiv
number
antisepticsdisinfect
quaternari
ammonium
compound
phenol
compound
associ
chlorhexidin
cetrimid
wide
use
human
medicin
seem
effect
hcov
except
ethanol
ad
recent
studi
investig
action
antisepticsdisinfect
hcov
suspens
test
contact
time
min
neutral
step
achiev
dilut
medium
cultur
povidoneiodin
free
iodin
caus
reduct
infect
virus
enough
claim
virucid
activ
moreov
obtain
reduct
hcov
titer
tenfold
increas
concentr
povidoneiodin
requir
product
ethanol
soap
bleach
assay
without
success
interf
biolog
viral
titrat
assay
also
highlight
import
neutral
step
necess
develop
mean
elimin
toxic
test
product
result
also
confirm
sarscov
kariwa
et
al
test
differ
formul
povidoneiodin
suspens
test
contact
time
min
neutral
step
achiev
chemic
addit
sodium
thiosulf
formul
reduc
viral
infect
detect
level
min
contacttim
result
obtain
ethanol
min
two
studi
conduct
laboratori
concern
hcov
sensit
two
wide
use
antisept
chlorhexidin
hexamidin
also
new
molecul
belong
calixaren
famili
studi
antisept
antivir
activ
assay
thank
suspens
test
efficaci
criterion
reduct
recommend
european
standard
novel
methodolog
gel
filtrat
neutral
step
develop
studi
use
homemad
reproduc
column
chlorhexidin
shown
time
concentrationdepend
antihcov
activ
allow
reduct
min
contact
time
figur
suffici
claim
antisept
antihcov
activ
hexamidin
show
activ
hcov
result
highlight
necess
evalu
activ
commonli
use
antisepticsdisinfect
differ
virus
sure
effici
develop
target
antisepsi
ii
develop
new
activ
noncytotox
molecul
second
studi
concern
antisept
antihcov
activ
two
calixaren
compound
ie
tetraparasulfonatocalix
aren
c
bithiazolyl
tetraparasulfonatocalix
aren
c
sbtz
molecul
attract
target
first
show
cytotox
c
sbtz
show
equival
even
better
activ
chlorhexidin
inde
activ
reach
almost
reduct
viral
titer
min
contact
time
figur
studi
need
calixaren
appear
interest
candid
new
antisepticsdisinfect
rabenau
et
al
achiev
studi
use
suspens
test
differ
organ
load
albumin
fc
sheep
erythrocyt
follow
recommend
european
standard
test
alcoholicbas
solut
isopropanol
ethanol
shown
allow
reduct
viral
titer
sec
whatev
ad
organ
load
also
investig
activ
three
surfac
instrument
disinfect
one
base
benzalkonium
chlorid
laurylamin
one
base
benzalkonium
chlorid
glutaraldehyd
didecyldimonium
chlorid
one
base
magnesium
monoperphthal
contact
time
still
accord
european
standard
min
sarscov
inactiv
disinfect
limit
detect
smaller
reduct
factor
regardless
type
organ
load
team
pursu
investig
evalu
sarscov
virucid
activ
differ
disinfect
base
alcohol
propanol
ethanol
use
hand
disinfect
aldehyd
formaldehyd
glutardialdehyd
glucoprotamin
wine
vinegar
methodolog
previous
describ
except
organ
load
fc
case
cytotox
effect
dilutionneutr
step
virusdisinfect
mixtur
membran
filter
allow
concentr
viral
particl
could
titter
retain
disinfect
result
record
tabl
variat
reduct
factor
due
filtrat
use
neutral
step
disinfect
toxic
strong
recent
studi
use
mhv
tgev
sarscov
surrog
thank
carrier
test
stainless
steel
surfac
chemic
neutral
step
antisarscov
efficaci
six
differ
formul
evalu
efficaci
criterion
reduct
viral
titer
min
contact
time
result
report
tabl
studi
reveal
first
behavior
differ
two
virus
chosen
surrog
rais
question
pertin
surrog
use
howev
sarscov
viru
requir
level
contain
laboratori
therefor
viru
surrog
allow
laboratori
dispos
type
equip
conduct
studi
produc
preciou
data
without
work
viru
alreadi
caus
worldwid
epidem
anoth
import
point
reveal
studi
ineffici
bleach
wide
use
disinfect
appli
usedilut
prescrib
manufactur
sattar
et
al
whose
result
record
tabl
found
higher
reduct
hcov
viral
titer
concentr
hypochlorit
greater
one
test
result
consist
concentrationdepend
effect
anoth
recent
studi
use
mhv
sarscov
surrog
carrier
test
petri
dish
antisept
antivir
activ
common
household
disinfect
antisept
contain
either
triclosan
chloroxylenol
sodium
hypochlorit
pine
oil
quaternari
compound
ethanol
investig
provid
least
reduct
viral
titer
within
sec
contact
time
consist
previou
result
despit
fact
studi
bring
vital
inform
also
highlight
necess
standard
antisepticsdisinfect
activ
evalu
also
develop
infield
test
order
better
appreci
true
action
antisepticsdisinfect
four
hcov
caus
mild
respiratori
ill
compar
sarscov
infecti
agent
involv
hospit
young
children
immunocompromis
adult
respiratori
tract
ill
also
involv
nosocomi
infect
moreov
although
sarsepidem
contain
possibl
reemerg
sarscov
emerg
anoth
zoonot
strain
remain
besid
absenc
specif
treatment
vaccin
hcov
known
show
signific
environment
resist
surviv
differ
biolog
fluid
respiratori
secret
fece
prove
furthermor
paramet
seem
benefit
hcov
stabil
effect
low
temperatur
high
rel
humid
protect
action
organ
materi
protect
effect
care
consid
develop
antisepticdisinfect
strategi
inde
often
involv
higher
quantiti
andor
concentr
antisepticdisinfect
product
higher
toxic
thu
effici
disinfect
process
includ
preclean
step
get
rid
organ
materi
old
wellknown
principl
antisepsisdisinfect
clean
thing
effici
disinfect
still
valuabl
final
regard
differ
studi
hcov
sensit
antisepticsdisinfect
formul
effici
within
adapt
contact
time
without
toostrong
toxic
instanc
consid
lack
effici
hcov
also
toxic
product
base
quaternari
ammonium
phenol
compound
avoid
larg
use
antisepticsdisinfect
ethanol
bleach
show
signific
activ
hcov
howev
critic
paramet
consid
especi
case
chlorinederiv
compound
presenc
organ
materi
could
prevent
antisept
activ
dosedepend
effect
hcov
povidoneiodin
chlorhexidin
associ
ethanol
andor
cetrimid
could
recommend
risk
hcov
contamin
contrari
anoth
wide
use
antisept
hexamidin
essenti
pursu
investig
hcov
environment
stabil
role
inanim
materi
spread
ii
sensit
antisepticsdisinfect
formul
standard
target
condit
iii
develop
new
effici
nontox
antisepticdisinfect
molecul
calixaren
compound
